Shanghai Junshi Bioscience Co., Ltd. clinical trial pipeline

3 trials changed in the last 30 days: 1 stopped, 1 with a notable change, 1 with a minor change only.

1. Stopped

   JS207 in NSCLC After Progression Following Platinum-based…JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

   Trial terminated

   Also in this update: Final enrollment: 18 participants (planned 66)

   Shanghai Junshi Bioscience Co., Ltd.·Phase 2· NCT06924606· Registry history of NCT06924606 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

2. Notable

   JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy…JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy · Relapsed/Refractory Diffuse Large B-Cell Lymphoma

   Recruitment opened

   Also in this update: Start date changed from estimate of Sep 24, 2026 to Oct 8, 2026

   Shanghai Junshi Bioscience Co., Ltd.·Phase 3· NCT07808827· Registry history of NCT07808827 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.